

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS INTRADISCAL ELECTROTHERMAL ANNULOPLASTY, RADIOFREQUENCY ANNULOPLASTY, BIACUPLASTY AND INTRAOSSEOUS BASIVERTEBRAL NERVE ABLATION
POLICY NUMBER	MP-1.124
Effective Date:	9/1/2023

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Percutaneous annuloplasty (e.g., intradiscal electrothermal annuloplasty, intradiscal radiofrequency annuloplasty, or intradiscal biacuplasty) for the treatment of chronic discogenic back pain is considered **investigational**.

Intraosseous radiofrequency ablation of the basivertebral nerve (e.g., Intrasept® system) for the treatment of vertebrogenic back pain is considered **investigational**.

There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with these procedures.

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross and subject to benefit variations as discussed in Section VI. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

III. DESCRIPTION/BACKGROUND

[TOP](#)

Electrothermal intradiscal annuloplasty therapies use radiofrequency energy sources to treat discogenic low back pain arising from annular tears. These annuloplasty techniques are designed to decrease pain arising from the annulus by thermocoagulating nerves in the disc and tightening of annular tissue.

Discogenic Low Back Pain

Discogenic low back pain is a common, multifactorial pain syndrome that involves low back pain without radicular symptoms findings, in conjunction with radiologically confirmed degenerative disc disease.

Treatment

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS INTRADISCAL ELECTROTHERMAL ANNULOPLASTY, RADIOFREQUENCY ANNULOPLASTY, BIACUPLASTY AND INTRAOSSEOUS BASIVERTEBRAL NERVE ABLATION
POLICY NUMBER	MP-1.124

Typical treatment includes conservative therapy with physical therapy and medication management, with potential for surgical decompression in more severe cases.

A number of electrothermal intradiscal procedures have been introduced to treat discogenic low back pain; they rely on various probe designs to introduce radiofrequency energy into the disc. It has been proposed that heat-induced denaturation of collagen fibers in the annular lamellae may stabilize the disc and potentially seal annular fissures. Pain reduction may occur through the thermal coagulation of nociceptors in the outer annulus.

With the intradiscal electrothermal annuloplasty procedure, a navigable catheter with an embedded thermal resistive coil is inserted posterolaterally into the disc annulus or nucleus. Using indirect radiofrequency energy, electrothermal heat is generated within the thermal resistive coil at a temperature of 90°C; the disc material is heated for up to 20 minutes. Proposed advantages of indirect electrothermal delivery of radiofrequency energy with intradiscal electrothermal annuloplasty include precise temperature feedback and control, and the ability to provide electrothermocoagulation to a broader tissue segment than would be allowed with a direct radiofrequency needle. Annuloplasty using a laser-assisted spinal endoscopy kit to coagulate the disc granulation tissue (percutaneous endoscopic laser annuloplasty) has also been described.

Percutaneous intradiscal radiofrequency thermocoagulation uses direct application of radiofrequency energy. With percutaneous intradiscal radiofrequency thermocoagulation, the radiofrequency probe is placed into the center of the disc, and the device is activated for only 90 seconds at a temperature of 70°C. The procedure is not designed to coagulate, burn, or ablate tissue. The Radionics Radiofrequency Disc Catheter System has been specifically designed for this purpose.

Intradiscal biacuplasty uses 2 cooled radiofrequency electrodes placed on the posterolateral sides of the intervertebral annulus fibrosus. It is believed that, by cooling the probes, a larger area may be treated than could occur with a regular needle probe.

Vertebral body endplates have been proposed as a source of lower back pain, caused by intraosseous nerves. The basivertebral nerve enters the posterior vertebral body and sends branches to the superior and inferior endplates. Vertebrogenic pain, transmitted via the basivertebral nerve, has been purported to occur with endplate damage or degeneration.

Regulatory Status

A variety of radiofrequency coagulation devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA), some of which are designed for disc nucleotomy. In 2002, the Oratec Nucleotomy Catheter (ORATEC Interventions, Menlo Park, CA, acquired by Smith & Nephew in 2002) was cleared for marketing by FDA through the 510(k) process. The predicate device was the SpineCATH® Intradiscal Catheter, which received FDA clearance for marketing

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS INTRADISCAL ELECTROTHERMAL ANNULOPLASTY, RADIOFREQUENCY ANNULOPLASTY, BIACUPLASTY AND INTRAOSSEOUS BASIVERTEBRAL NERVE ABLATION
POLICY NUMBER	MP-1.124

in 1999. The Radionics (a division of Tyco Healthcare group) Radiofrequency Disc Catheter System received marketing clearance by FDA through the 510(k) process in 2000. FDA product code: GEI.

In 2005, the Baylis Pain Management Cooled Probe was also cleared for marketing by FDA through the 510(k) process. It is intended for use “in conjunction with the Radio Frequency Generator to create radiofrequency lesions in nervous tissue.” FDA product code: GXI.

The Intracept Intraosseous Nerve Ablation System “is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least 6 months duration that has not responded to at least 6 months of conservative care”. FDA reviewed the device and issued a substantially equivalent designation in August 2017 (K170827). In March of 2022, FDA issued a substantially equivalent designation for an additional Intracept Intraosseous Nerve Ablation System (Relieva Medsystems, Inc.; K213836). The prior device (K170827) is listed as the reference access instrument and the new indication adds a description of accompanying use case features, “...is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change).” FDA product code: GXI.

Note: This evidence review does not address disc nucleoplasty, a technique based on the bipolar RF device (Coblation®; ArthroCare, Austin, TX, acquired by Smith & Nephew, 2014). With the coblation system, a bipolar radiofrequency device is used to provide lower energy treatment to the intervertebral disc, which is designed to provide tissue removal with minimal thermal damage to collateral tissue. Disc nucleoplasty is closer in concept to a laser discectomy in that tissue is removed or ablated to provide decompression of a bulging disc.

IV. RATIONALE

[TOP](#)

Summary of Evidence

For individuals who have discogenic back pain who receive intradiscal electrothermal annuloplasty, the evidence includes a small number of randomized controlled trials (RCTs). Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Two RCTs on intradiscal electrothermal annuloplasty reported conflicting results, with one reporting benefit for intradiscal electrothermal annuloplasty and the other reporting no benefit. Further study in a sham-controlled trial with a representative population of patients is needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS INTRADISCAL ELECTROTHERMAL ANNULOPLASTY, RADIOFREQUENCY ANNULOPLASTY, BIACUPLASTY AND INTRAOSSEOUS BASIVERTEBRAL NERVE ABLATION
POLICY NUMBER	MP-1.124

For individuals who have discogenic back pain who receive intradiscal radiofrequency annuloplasty, the evidence includes 2 RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Neither RCT found evidence of benefit with the treatment. More sham-controlled trials are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have discogenic back pain who receive intradiscal biacuplasty, the evidence includes 2 industry sponsored RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. One trial reported significant improvements at 6 months post-treatment, but not at 1 and 3 months. The other trial also showed a significant reduction in visual analog scale scores at 6 months that appeared to continue to the 12-month follow-up; however, it is unclear whether this trial was sufficiently powered. More sham-controlled trials are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have vertebrogenic back pain who receive intraosseous ablation of basivertebral nerves, the evidence includes 2 RCTs (the SMART and INTRACEPT trials). Relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. The SMART trial did not find a difference in the Oswestry Disability Index between patients treated with basivertebral nerve ablation or sham control at 3 months using an intent-to-treat analysis. Although the per protocol analysis showed a significant difference; results for the per protocol population at 12 months were not significantly different. Additionally, 73% of patients in this trial crossed over to the active treatment group at 12 months and therefore, long-term comparative data are not available. The INTRACEPT trial found a significant difference in the Oswestry Disability Index and other pain scores between patients treated with basivertebral nerve ablation and standard care at 3 months. Comparative data at 6 months post randomization showed similar results. However, 92% of patients initially assigned to standard care elected to cross over to receive early basivertebral nerve ablation, thus, long-term comparative data beyond 6 months are not available. Additional limitations to this RCT include lack of a sham control. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

V. DEFINITIONS

[TOP](#)

ANNULAR LAMELLAE are circular plates of collagen fibers found in secondary (mature, adult) bone.

INTERVERTEBRAL DISC is the fibrocartilaginous tissue between the vertebral bodies. The outer portion is the annulus fibrosus; the inner portion is the nucleus pulposus. The disc is the shock absorber, or cushion, and permits movement.

NOCICEPTORS are free nerve endings that are receptors for painful stimuli.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS INTRADISCAL ELECTROTHERMAL ANNULOPLASTY, RADIOFREQUENCY ANNULOPLASTY, BIACUPLASTY AND INTRAOSSEOUS BASIVERTEBRAL NERVE ABLATION
POLICY NUMBER	MP-1.124

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits, and which require preauthorization. There are different benefit plan designs in each product administered by Capital BlueCross. Members and providers should consult the member's health benefit plan for information or contact Capital BlueCross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital BlueCross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital BlueCross' Provider Services or Member Services. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational and therefore not covered:

Procedure Codes							
22526	22527	64628	64629				

IX. REFERENCES

[TOP](#)

1. U.S. Food & Drug Administration. K213836 Intracept Intraosseous Nerve Ablation System 510k Summary. 2022
2. Pauza KJ, Howell S, Dreyfuss P, et al. A randomized, placebo-controlled trial of intradiscal electrothermal therapy for the treatment of discogenic low back pain. *Spine J.* Jan-Feb 2004;4(1):27-35. PMID 14749191
3. Freeman BJ, Fraser RD, Cain CM, et al. A randomized, double-blind, controlled trial: intradiscal electrothermal therapy versus placebo for the treatment of chronic discogenic low

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS INTRADISCAL ELECTROTHERMAL ANNULOPLASTY, RADIOFREQUENCY ANNULOPLASTY, BIACUPLASTY AND INTRAOSSEOUS BASIVERTEBRAL NERVE ABLATION
POLICY NUMBER	MP-1.124

back pain. Spine (Phila Pa 1976). Nov 1, 2005;30(21):2369-2377; discussion 2378. PMID 16261111

4. *Barendse GA, van Den Berg SG, Kessels AH, et al. Randomized controlled trial of percutaneous intradiscal radiofrequency thermocoagulation for chronic discogenic back pain: lack of effect from a 90-second 70 C lesion. Spine (Phila Pa 1976). Feb 1, 2001;26(3):287-292. PMID 11224865*
5. *Kvarstein G, Mawe L, Indahl A, et al. A randomized double-blind controlled trial of intra-annular radiofrequency thermal disc therapy--a 12-month follow-up. Pain. Oct 2009;145(3):279-286. PMID 19647940*
6. *Kapur L, Vrooman B, Sarwar S, et al. A randomized, placebo-controlled trial of transdiscal radiofrequency, biacuplasty for treatment of discogenic lower back pain. Pain Med. Mar 2013;14(3):362-373. PMID 23279658*
7. *Kapur L, Vrooman B, Sarwar S, et al. Radiofrequency intradiscal biacuplasty for treatment of discogenic lower back pain: a 12-month follow-up. Pain Med. Mar 2015;16(3):425-431. PMID 25339501*
8. *Desai MJ, Kapur L, Petersohn JD, et al. A prospective, randomized, multicenter, open-label clinical trial comparing intradiscal biacuplasty to conventional medical management for discogenic lumbar back pain. Spine (Phila Pa 1976). Jul 01, 2016;41(13):1065-1074. PMID 26689579*
9. *Desai MJ, Kapur L, Petersohn JD, et al. Twelve-month follow-up of a randomized clinical trial comparing intradiscal biacuplasty to conventional medical management for discogenic lumbar back pain. Pain Med. Apr 1, 2017;18(4):751-763. PMID 27570246*
10. *Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: a prospective randomized double-blind sham-controlled multi-center study. Eur Spine J. May 2018; 27(5): 1146-1156. PMID 29423885*
11. *Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous Basivertebral Nerve Ablation for the Treatment of Chronic Low Back Pain: 2-Year Results From a Prospective Randomized Double-Blind Sham-Controlled Multicenter Study. Int J Spine Surg. Apr 2019; 13(2): 110-119. PMID 31131209*
12. *Fischgrund JS, Rhyne A, Macadaeg K, et al. Long-term outcomes following intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 5-year treatment arm results from a prospective randomized double-blind sham-controlled multi-center study. Eur Spine J. Aug 2020; 29(8): 1925-1934. PMID 32451777*
13. *Khalil JG, Smuck M, Koreckij T, et al. A prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain. Spine J. Oct 2019; 19(10): 1620-1632. PMID 31229663*
14. *Smuck M, Khalil J, Barrette K, et al. Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 12-month results. Reg Anesth Pain Med. Aug 2021; 46(8): 683-693. PMID 34031220*

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS INTRADISCAL ELECTROTHERMAL ANNULOPLASTY, RADIOFREQUENCY ANNULOPLASTY, BIACUPLASTY AND INTRAOSSEOUS BASIVERTEBRAL NERVE ABLATION
POLICY NUMBER	MP-1.124

15. Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: Guidance and recommendations. *Pain Physician*. Apr 2013;16(2 Suppl):S49-S283. PMID 23615883
16. Boswell MV, Trescot AM, Datta S, et al. Interventional techniques: evidence-based practice guidelines in the management of chronic spinal pain. *Pain Physician*. Jan 2007;10(1):7-111. PMID 17256025
17. Lorio M, Clerk-Lamalice O, Beall DP, et al. International Society for the Advancement of Spine Surgery Guideline-Intraosseous Ablation of the Basivertebral Nerve for the Relief of Chronic Low Back Pain. *Int J Spine Surg*. Feb 2020; 14(1): 18-25. PMID 32128298
18. National Institute for Health and Care Excellence. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain [IPG545]. 2016
19. National Institute for Health and Care Excellence. Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica [IPG544]. 2016
20. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Thermal Intradiscal Procedures (TIPs) (150.11)
21. Blue Cross Blue Shield Association Medical Policy Reference Manual. 7.01.72. Percutaneous Intradiscal Electrothermal Annuloplasty, Radiofrequency Annuloplasty and Biacuplasty. May 2023

X. POLICY HISTORY

[TOP](#)

MP 1.124	CAC 7/26/11 New policy. Adopt BCBSA. BCBSA language adoption did not change intent of policy statements. Other minimally invasive procedures extracted from CBC MP-1.021 Image-Guided Minimally Invasive Lumbar Decompression (IG-MLD) for Spinal Stenosis (formerly Minimally Invasive Disc Procedures) and separated into individual policies. See MP 1.123 Automated Percutaneous Discectomy, MP 1.125 Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency Coblation (Nucleoplasty) and MP 1.126 Minimally Invasive Lumbar Interbody Fusion.
	CAC 10/30/12 Consensus review. References updated, no changes to the policy statements. FEP variation revised to refer to the FEP policy manual. Codes reviewed 10/18/2012
	CAC 11/26/13 Consensus review. References updated, no changes to the policy statements. Rationale added.
	CAC 11/25/14 Consensus review. No change to policy statements. References and rationale updated. Coding Reviewed 11/07/2014
	CAC 11/24/15 Consensus review. No change to the policy statements. Reference and rationale update. Coding reviewed.
	CAC 11/29/16 Consensus review. No change to the policy statements. References updated. Variations reformatted. Coding reviewed.

MEDICAL POLICY

POLICY TITLE	PERCUTANEOUS INTRADISCAL ELECTROTHERMAL ANNULOPLASTY, RADIOFREQUENCY ANNULOPLASTY, BIACUPLASTY AND INTRAOSSEOUS BASIVERTEBRAL NERVE ABLATION
POLICY NUMBER	MP-1.124

	CAC 11/28/17 Consensus review. Title changed to “Percutaneous Intradiscal Electrothermal Annuloplasty, Radiofrequency Annuloplasty, and Biacuplasty.” Policy statement terminology revised to reflect the changes in the title, but the intent is unchanged. Cross-Reference, Description/Background, Rationale and Reference sections updated.
	7/20/18 Consensus review. No change to policy statements. References reviewed. Rationale condensed.
	10/30/18 Coding review completed.
	5/17/19 Consensus review. No change to policy statements. References reviewed.
	5/12/20 Consensus review. No change to policy statements. References and Summary of Evidence section updated. Language under Disclaimer, Product Variations and Benefit Variations sections revised. Coding reviewed.
	3/18/2021 Consensus review. No change to policy statement. References updated.
	12/1/2021 Administrative update. New codes 64628 and 64629 added to policy. Effective 1/1/2022.
	05/26/2022 Minor review. Policy title changed to include Intraosseous Basivertebral Nerve Ablation. Policy statement updated to include “Intraosseous radiofrequency ablation of the basivertebral nerve (e.g., Intrasept® system) for the treatment of vertebrogenic back pain is considered investigational”. FEP language updated. Background, Rationale and References revised.
	05/30/2023 Consensus review. No change to policy statement. Background, Rationale and References updated.

[Top](#)

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies